About Auron Therapeutics
Auron Therapeutics is a company based in Wellesley (United States) founded in 2018 by Kate Yen, Matt Vander Heiden, Eytan Stein, and Ross Levine.. Auron Therapeutics has raised $103.84 million across 4 funding rounds from investors including Lilly, Genedit and Creyon Bio. Auron Therapeutics offers products and services including AURIGIN and AUTX-703. Auron Therapeutics operates in a competitive market with competitors including Syndax, Annexon, Adicet Bio, ImmunoACT and Orca Bio, among others.
- Headquarter Wellesley, United States
- Founders Kate Yen, Matt Vander Heiden, Eytan Stein, Ross Levine
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$103.84 M (USD)
in 4 rounds
-
Latest Funding Round
$27 M (USD), Series B
Feb 04, 2025
-
Investors
Lilly
& 12 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Auron Therapeutics
Auron Therapeutics offers a comprehensive portfolio of products and services, including AURIGIN and AUTX-703. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
AI-driven tool for identifying cell state-specific targets in drug discovery
Targets KAT2A/B for treating cancers like SCLC and AML
Unlock access to complete
Unlock access to complete
Funding Insights of Auron Therapeutics
Auron Therapeutics has successfully raised a total of $103.84M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $27 million completed in February 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series B — $27.0M
-
First Round
First Round
(16 Dec 2020)
- Investors Count 13
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2025 | Amount | Series B - Auron Therapeutics | Valuation | DCVC | |
| Dec, 2024 | Amount | Series A - Auron Therapeutics | Valuation |
investors |
|
| Jul, 2022 | Amount | Series A - Auron Therapeutics | Valuation | Creyon Bio , Totus Medicines |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Auron Therapeutics
Auron Therapeutics has secured backing from 13 investors, including venture fund, angel, and institutional investors. Prominent investors backing the company include Lilly, Genedit and Creyon Bio. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on multiple sectors
|
Founded Year | Domain | Location | |
|
Early-stage venture capital investments in healthcare and biotech are made.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Auron Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Auron Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Auron Therapeutics Comparisons
Competitors of Auron Therapeutics
Auron Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Syndax, Annexon, Adicet Bio, ImmunoACT and Orca Bio, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Targeted therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| domain | founded_year | HQ Location |
Immune cell therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Cell therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders
|
|
| domain | founded_year | HQ Location |
Ossium Health is focused on bioengineering for improved health.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Auron Therapeutics
Frequently Asked Questions about Auron Therapeutics
When was Auron Therapeutics founded?
Auron Therapeutics was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Where is Auron Therapeutics located?
Auron Therapeutics is headquartered in Wellesley, United States. It is registered at Wellesley, Massachusetts, United States.
Who is the current CEO of Auron Therapeutics?
Kate Yen is the current CEO of Auron Therapeutics. They have also founded this company.
Is Auron Therapeutics a funded company?
Auron Therapeutics is a funded company, having raised a total of $103.84M across 4 funding rounds to date. The company's 1st funding round was a Series A of $48M, raised on Dec 16, 2020.
What does Auron Therapeutics do?
Auron Therapeutics was established in 2018 in Wellesley, United States, within the biotechnology sector focused on oncology. Proprietary differentiation therapy is developed for hematologic malignancies, where endogenous cellular programs are reactivated to induce tumor cell maturation and shift cancer tissue toward a normal phenotype. This approach targets conditions such as acute promyelocytic leukemia by converting malignant promyelocytes into non-cancerous neutrophils.
Who are the top competitors of Auron Therapeutics?
What products or services does Auron Therapeutics offer?
Auron Therapeutics offers AURIGIN and AUTX-703.
Who are Auron Therapeutics's investors?
Auron Therapeutics has 13 investors. Key investors include Lilly, Genedit, Creyon Bio, Mubadala, and Totus Medicines.